Response to anti-PD1 immunotherapy in patients with metastatic cutaneous sarcoma: case reports and literature review

Area of Science:

• Oncology
• Dermatology
• Immunotherapy

Background:

• Dermal sarcomas are rare mesenchymal malignancies with limited treatment options in advanced stages.
• Current therapies like chemotherapy and targeted agents offer short-lived benefits for metastatic disease.
• The efficacy of immune-checkpoint blockade in sarcoma patients is under investigation.

Observation:

• Three cases of dermal sarcomas exhibiting high tumor mutational burden (TMB) and PD-L1 expression were analyzed.
• These biomarkers are known predictors of immunotherapy response in other metastatic cancers.
• The study focused on the potential of anti-PD1 agents in this patient cohort.

Findings:

• Two out of three patients with high TMB and PD-L1 expression demonstrated positive responses to anti-PD1 therapy.
• This suggests a potential role for immune-checkpoint inhibitors in treating specific dermal sarcoma subtypes.
• The observed responses indicate that TMB and PD-L1 may be relevant biomarkers in this context.

Implications:

• Immune-checkpoint blockade, specifically anti-PD1 agents, may offer a viable treatment avenue for select patients with advanced dermal sarcomas.
• High TMB and PD-L1 expression could identify patients likely to benefit from such immunotherapies.
• Further research is warranted to establish the efficacy and optimal use of immunotherapy in dermal sarcoma treatment.